{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:52:55Z","timestamp":1790704375358,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009464","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T00:00:00Z","timestamp":1447286400000}}],"reference-count":177,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009464.pub2","type":"journal-article","created":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T10:40:43Z","timestamp":1447324843000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy"],"prefix":"10.1002","volume":"2021","author":[{"given":"Lesley A","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Psychology, Social Work and Public Health; Oxford Brookes University; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredric","family":"Azariah","sequence":"additional","affiliation":[{"name":"School of Health and Social Care; Oxford Brookes University; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verna TC","family":"Lavender","sequence":"additional","affiliation":[{"name":"Guy\u2019s Cancer Academy; Guy's and St Thomas' NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola S","family":"Stoner","sequence":"additional","affiliation":[{"name":"Pharmacy; Oxford University Hospitals NHS Trust; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Bettiol","sequence":"additional","affiliation":[{"name":"Department of Medicine and Paramedicine, Faculty of Health; University of Tasmania; Hobart Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,12]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD009464.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/bjc.1983.247","article-title":"Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy","volume":"48","author":"Ahmedzai","year":"1983","journal-title":"British Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD009464.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/0003-4819-91-6-819","article-title":"Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation","volume":"91","author":"Chang","year":"1979","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD009464.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/1097-0142(19810401)47:7<1746::AID-CNCR2820470704>3.0.CO;2-4","article-title":"A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy","volume":"47","author":"Chang","year":"1981","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02934575","article-title":"Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study","volume":"3","author":"Crawford","year":"1986","journal-title":"Medical Oncology and Tumor Pharmacotherapy"},{"issue":"8-9 Suppl","key":"10.1002\/14651858.CD009464.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1002\/j.1552-4604.1981.tb02576.x","article-title":"Nabilone: an effective antiemetic in patients receiving cancer chemotherapy","volume":"21","author":"Einhorn","year":"1981","journal-title":"Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD009464.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-91-6-825","article-title":"Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo","volume":"91","author":"Frytak","year":"1979","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0007|cit7","first-page":"24","article-title":"Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin [French]","volume":"37","author":"George","year":"1983","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0008|cit8","first-page":"163","article-title":"Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol","volume":"68","author":"Gralla RJ Tyson LB Bordin","year":"1984","journal-title":"Cancer Treatment Reports"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Herman TS Einhorn LH Jones SE Nagy C Chester AB Dean JC Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy New England Journal of Medicine 1979 300 1295 7","DOI":"10.1056\/NEJM197906073002302"},{"issue":"Suppl B","key":"10.1002\/14651858.CD009464.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0305-7372(82)80032-7","article-title":"A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy","volume":"9","author":"Johansson","year":"1982","journal-title":"Cancer Treatment Reviews"},{"issue":"Suppl B","key":"10.1002\/14651858.CD009464.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0305-7372(82)80035-2","article-title":"A multi-institutional phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting","volume":"9","author":"Jones","year":"1982","journal-title":"Cancer Treatment Reviews"},{"issue":"61","key":"10.1002\/14651858.CD009464.pub2-BIB0012|cit12","first-page":"1014","article-title":"Double blind trial of delta-9-tetrahydrocannabinol (THC) versus placebo as an adjunct to prochlorperazine for chemotherapy-induced vomiting","volume":"33","author":"Kleinman","year":"1983","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"5","key":"10.1002\/14651858.CD009464.pub2-BIB0013|cit13","first-page":"338","article-title":"Delta 9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo","volume":"21","author":"Kluin-Neleman","year":"1979","journal-title":"Veterinary & Human Toxicology"},{"issue":"6","key":"10.1002\/14651858.CD009464.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/0885-3924(91)90026-Z","article-title":"Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting","volume":"6","author":"Lane","year":"1991","journal-title":"Journal of Pain and Symptom Management"},{"issue":"Suppl B","key":"10.1002\/14651858.CD009464.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0305-7372(82)80036-4","article-title":"Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients","volume":"9","author":"Levitt","year":"1982","journal-title":"Cancer Treatment Reviews."},{"issue":"3","key":"10.1002\/14651858.CD009464.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF00175407","article-title":"Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy","volume":"6","author":"McCabe","year":"1988","journal-title":"Investigational New Drugs"},{"issue":"4","key":"10.1002\/14651858.CD009464.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00000421-198508000-00013","article-title":"A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy","volume":"8","author":"Niiranen","year":"1985","journal-title":"American Journal of Clinical Oncology: Cancer Clinical Trials"},{"issue":"8-9 Suppl","key":"10.1002\/14651858.CD009464.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"76S","DOI":"10.1002\/j.1552-4604.1981.tb02578.x","article-title":"Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine","volume":"21","author":"Orr","year":"1981","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD009464.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00256701","article-title":"Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis","volume":"17","author":"Pomeroy","year":"1986","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Sallan SE Zinberg NE Frei E Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy New England Journal of Medicine 1975 293 795 7","DOI":"10.1056\/NEJM197510162931603"},{"issue":"2-3","key":"10.1002\/14651858.CD009464.pub2-BIB0021|cit21","first-page":"219","article-title":"Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis","volume":"64","author":"Steele","year":"1980","journal-title":"Cancer Treatment Reports"},{"issue":"4","key":"10.1002\/14651858.CD009464.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/1097-0142(19820815)50:4<636::AID-CNCR2820500404>3.0.CO;2-4","article-title":"Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine","volume":"50","author":"Ungerleider","year":"1982","journal-title":"Cancer"},{"issue":"Suppl B","key":"10.1002\/14651858.CD009464.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0305-7372(82)80034-0","article-title":"Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy","volume":"9","author":"Wada","year":"1982","journal-title":"Cancer Treatment Reviews"},{"issue":"11","key":"10.1002\/14651858.CD009464.pub2-BIB0024|cit24","first-page":"843","article-title":"Prevention of chemotherapy-induced nausea and vomiting in patients with cancer","volume":"38","author":"Aapro","year":"1981","journal-title":"Arizona Medicine"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0268-960X(87)90019-1","article-title":"Mechanisms and management of chemotherapy-induced nausea and vomiting","volume":"1","author":"Allan","year":"1987","journal-title":"Blood Reviews"},{"issue":"5","key":"10.1002\/14651858.CD009464.pub2-BIB0026|cit26","first-page":"639","article-title":"Delta-9-tetrahydrocannabinol as an antiemetic","volume":"38","author":"Anderson","year":"1981","journal-title":"American Journal of Hospital Pharmacy"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0027|cit27","unstructured":"Artim R Dibella N Tetrahydrocannabinol plus prochlorperazine for refractory nausea and vomiting Proceedings of the 19th annual meeting of the American Society of Clinical Oncology 1983 85"},{"issue":"6324","key":"10.1002\/14651858.CD009464.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1136\/bmj.284.6324.1211-a","article-title":"Therapeutic potential of cannabinoids","volume":"284","author":"Bateman","year":"1982","journal-title":"British Medical Journal Clinical Research Ed"},{"issue":"1-2","key":"10.1002\/14651858.CD009464.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jep.2006.02.001","article-title":"Cannabinoids in medicine: a review of their therapeutic potential","volume":"105","author":"Ben Amar","year":"2006","journal-title":"Journal of Ethnopharmacology"},{"issue":"8 suppl","key":"10.1002\/14651858.CD009464.pub2-BIB0030|cit30","first-page":"9","article-title":"Evolving paradigms in chemotherapy-induced nausea and vomiting and symptom management for the breast cancer patient","volume":"22","author":"Biedrzycki","year":"2007","journal-title":"ONS Connect"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0031|cit31","first-page":"514","article-title":"A randomized blinded clinical trial comparing delta-9-tetrahydrocannabinol (THC) and hydroxizine (HZ) as antiemetics (AE) for cancer chemotherapy (CT)","volume":"23","author":"Broder","year":"1982","journal-title":"Proceedings of the American Association for Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-99-1-106","article-title":"Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues","volume":"99","author":"Carey","year":"1983","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD009464.pub2-BIB0033|cit33","first-page":"946","article-title":"Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial","volume":"79","author":"Chan","year":"1987","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Chang AE Shiling DJ Stillman RC A prospective randomized trial of delta-9-tetrahydrocannabinol (THC) as an antiemetic in patients receiving high dose methotrexate (MTX) American Society of Clinical Oncology 1979 No C-357","DOI":"10.7326\/0003-4819-91-6-819"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0035|cit35","first-page":"109","article-title":"Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting","volume":"69","author":"Citron ML Herman TS Vreeland","year":"1985","journal-title":"Cancer Treatment Reports"},{"issue":"11","key":"10.1002\/14651858.CD009464.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/106002808101501104","article-title":"A critical review of the safety and antiemetic efficacy of delta-9- tetrahydrocannabinol","volume":"15","author":"Cocchetto","year":"1981","journal-title":"Drug Intelligence and Clinical Pharmacy"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Colls BM Cannabis and cancer chemotherapy Lancet 1980 1 1187 8","DOI":"10.1016\/S0140-6736(80)91642-6"},{"issue":"662","key":"10.1002\/14651858.CD009464.pub2-BIB0038|cit38","first-page":"449","article-title":"The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy","volume":"91","author":"Colls","year":"1980","journal-title":"New Zealand Medical Journal"},{"issue":"Suppl B","key":"10.1002\/14651858.CD009464.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0305-7372(82)80038-8","article-title":"Use of nabilone in the treatment of chemotherapy-induced vomiting in an outpatient setting","volume":"9","author":"Cone","year":"1982","journal-title":"Cancer Treatment Reviews"},{"issue":"8","key":"10.1002\/14651858.CD009464.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/cbdv.200790146","article-title":"On the pharmacological properties of 9-tetrahydrocannabinol (THC)","volume":"4","author":"Costa","year":"2007","journal-title":"Chemistry and Biodiversity"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Cotter J Efficacy of crude marijuana and synthetic delta-9-tetrahydrocannabinol as treatment for chemotherapy-induced nausea and vomiting: a systematic literature review Oncology Nursing Forum 2009 36 3 345 52","DOI":"10.1188\/09.ONF.345-352"},{"issue":"8-9 Suppl","key":"10.1002\/14651858.CD009464.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1002\/j.1552-4604.1981.tb02572.x","article-title":"Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy","volume":"21","author":"Cronin","year":"1981","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/00023210-200317030-00004","article-title":"Therapeutic potential of cannabinoids in CNS disease","volume":"17","author":"Croxford","year":"2003","journal-title":"CNS Drugs"},{"issue":"6499","key":"10.1002\/14651858.CD009464.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bmj.291.6499.864","article-title":"Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs","volume":"291","author":"Cunningham","year":"1985","journal-title":"British Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD009464.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0277-5379(88)90300-8","article-title":"A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues","volume":"24","author":"Cunningham","year":"1988","journal-title":"European Journal of Cancer and Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD009464.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/adc.61.5.502","article-title":"Nabilone: an alternative antiemetic for cancer chemotherapy","volume":"61","author":"Dalzell","year":"1986","journal-title":"Archives of Disease in Childhood"},{"issue":"7","key":"10.1002\/14651858.CD009464.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3390\/ph3072163","article-title":"Cannabinoid-induced hyperemesis: a conundrum-from clinical recognition to basic science mechanisms","volume":"3","author":"Darmani","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00520-006-0180-0","article-title":"The emerging role of cannabinoid neuromodulators in symptom management","volume":"15","author":"Davis","year":"2007","journal-title":"Supportive Care in Cancer"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1517\/13543784.17.1.85","article-title":"Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain","volume":"17","author":"Davis","year":"2008","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"4","key":"10.1002\/14651858.CD009464.pub2-BIB0050|cit50","first-page":"319","article-title":"Adverse reactions to delta-9-tetrahydrocannabinol given as an antiemetic in a multicenter study","volume":"6","author":"Devine","year":"1987","journal-title":"Clinical Pharmacy"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0051|cit51","first-page":"143","article-title":"The control of cancer chemotherapy-induced nausea and vomiting","volume":"10","author":"Dodds","year":"1985","journal-title":"Journal of Clinical Hospital Pharmacy"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0052|cit52","first-page":"14","article-title":"Serious reactions to oral delta-9-tetrahydrocannabinol in cancer chemotherapy patients","volume":"3","author":"Dow","year":"1984","journal-title":"Clinical Pharmacy"},{"issue":"5","key":"10.1002\/14651858.CD009464.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2125.2010.03743.x","article-title":"Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting","volume":"70","author":"Duran","year":"2010","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"12","key":"10.1002\/14651858.CD009464.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"657","DOI":"10.5694\/j.1326-5377.1979.tb127271.x","article-title":"Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol","volume":"2","author":"Ekert","year":"1979","journal-title":"Medical Journal of Australia"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2007.0004","article-title":"Antiemesis: clinical practice guidelines in oncology","volume":"5","author":"Ettinger","year":"2007","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/annonc\/mdq600","article-title":"Update and new trends in antiemetic therapy: the continuing need for novel therapies","volume":"22","author":"Feyer","year":"2011","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD009464.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/07357908409040312","article-title":"Pharmacologic treatment of chemotherapy-induced nausea and vomiting","volume":"2","author":"Fiore","year":"1984","journal-title":"Cancer Investigation"},{"issue":"13","key":"10.1002\/14651858.CD009464.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1056\/NEJM197909273011318","article-title":"Nabilone as an antiemetic","volume":"301","author":"Fox","year":"1979","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/157488909788453031","article-title":"Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications","volume":"4","author":"Galal","year":"2009","journal-title":"Recent Patents on CNS Drug Discovery"},{"issue":"9","key":"10.1002\/14651858.CD009464.pub2-BIB0060|cit60","first-page":"51","article-title":"Nausea and vomiting induced by cancer chemotherapy. Review of Cannabis and its antiemetic effects","volume":"1","author":"Gallego Fernandez","year":"1984","journal-title":"Farmacia Clinica"},{"issue":"14","key":"10.1002\/14651858.CD009464.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/BF01487619","article-title":"Levonantradol for the treatment of chemotherapy-induced nausea and vomiting","volume":"61","author":"Gerhartz","year":"1983","journal-title":"Klinische Wochenschrift"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2174\/157488910789753521","article-title":"Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists","volume":"5","author":"Gerra","year":"2010","journal-title":"Recent Patents on CNS Drug Discovery"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD009464.pub2-BIB0063|cit63","first-page":"20","article-title":"Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting","volume":"24","author":"Goodman","year":"1997","journal-title":"Oncology Nursing Forum"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009464.pub2-BIB0064|cit64","first-page":"21","article-title":"Cancer cachexia and cannabinoids","volume":"6","author":"Gorter","year":"1999","journal-title":"Forschende Komplementarmedizin"},{"issue":"4","key":"10.1002\/14651858.CD009464.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0268-960X(89)90029-5","article-title":"Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens","volume":"3","author":"Grunberg","year":"1989","journal-title":"Blood Reviews"},{"issue":"10","key":"10.1002\/14651858.CD009464.pub2-BIB0066|cit66","first-page":"745","article-title":"Cannabinoids: potential anticancer agents","volume":"3","author":"Guzman","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF00257128","article-title":"Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy","volume":"13","author":"Heim","year":"1984","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD009464.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s005200050155","article-title":"Corticosteroids, dopamine antagonists and other drugs","volume":"6","author":"Herrstedt","year":"1998","journal-title":"Supportive Care in Cancer"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/ncponc1021","article-title":"Antiemetics: an update and the MASCC guidelines applied in clinical practice","volume":"5","author":"Herrstedt","year":"2008","journal-title":"Nature Clinical Practice Oncology"},{"issue":"3","key":"10.1002\/14651858.CD009464.pub2-BIB0070|cit70","first-page":"1232","article-title":"Levonantradol in the treatment of nausea and vomiting caused by cytostatic drugs (author's translation) clinical studies [German]","volume":"107","author":"Higi","year":"1982","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"10","key":"10.1002\/14651858.CD009464.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/BF01726904","article-title":"New aspects in the antiemetic therapy of cytostatic drug-induced vomiting [German]","volume":"62","author":"Hiller","year":"1984","journal-title":"Klinische Wochenschrift"},{"issue":"8","key":"10.1002\/14651858.CD009464.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/0277-5379(83)90032-9","article-title":"A randomised multicentre single blind comparison of cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy","volume":"19","author":"Hutcheon","year":"1983","journal-title":"European Journal of Cancer and Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.critrevonc.2006.08.003","article-title":"Comparative activity of antiemetic drugs","volume":"61","author":"Jordan","year":"2007","journal-title":"Critical Reviews in Oncology-Hematology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009464.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1007\/s00520-010-0994-7","article-title":"Antiemetics in children receiving chemotherapy. MASCC\/ESMO guideline update 2009","volume":"19","author":"Jordan","year":"2011","journal-title":"Supportive Care in Cancer"},{"issue":"8","key":"10.1002\/14651858.CD009464.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5694\/j.1326-5377.1985.tb123059.x","article-title":"Recent advances in the prevention or reduction of cytotoxic-induced emesis","volume":"143","author":"Kearsley","year":"1985","journal-title":"Medical Journal of Australia"},{"issue":"4","key":"10.1002\/14651858.CD009464.pub2-BIB0076|cit76","first-page":"335","article-title":"Levonantradol effectiveness in cancer patients resistant to conventional anti-emetics","volume":"8","author":"Kenny","year":"1982","journal-title":"Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0077|cit77","first-page":"900","article-title":"Tetrahydrocannabinol as antiemetic in patients treated with cytostatics: double blind crossover trial against placebo","volume":"125","author":"Kluin-Nelemans","year":"1981","journal-title":"Nederlands Tijdschrift voor Geneeskunde"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0078|cit78","first-page":"90","article-title":"9-Tetrahydrocannabinol (THC) as an anti-emetic in patients treated with cancer chemotherapy. A double-blind cross-over trial against placebo","volume":"24","author":"Kluin-Nelemans","year":"1981","journal-title":"Netherlands Journal of Medicine"},{"issue":"9 Suppl","key":"10.1002\/14651858.CD009464.pub2-BIB0079|cit79","first-page":"19","article-title":"New directions in managing chemotherapy-related emesis","volume":"5","author":"Krasnow","year":"1991","journal-title":"Oncology"},{"issue":"5","key":"10.1002\/14651858.CD009464.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/pauz.200700236","article-title":"The magic plant as an antiemetic. Cannabinoids for treatment of nausea and vomiting [German]","volume":"36","author":"Kreutz","year":"2007","journal-title":"Pharmazie in Unserer Zeit"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0081|cit81","unstructured":"Lane M Vogel CL Ferguson J Krasnow S Saiers JH Hamm J Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting Proceedings of the American Society of Clinical Oncology 1989 8 326, Abstract 1269"},{"issue":"6","key":"10.1002\/14651858.CD009464.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/00000421-199012000-00006","article-title":"Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy","volume":"13","author":"Lane","year":"1990","journal-title":"American Journal of Clinical Oncology: Cancer Clinical Trials"},{"issue":"Suppl B","key":"10.1002\/14651858.CD009464.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0305-7372(82)80029-7","article-title":"Treatment of nausea and vomiting caused by cancer chemotherapy","volume":"9","author":"Laszlo","year":"1982","journal-title":"Cancer Treatment Reviews"},{"issue":"8-9 Suppl","key":"10.1002\/14651858.CD009464.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"103S","DOI":"10.1002\/j.1552-4604.1981.tb02583.x","article-title":"Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications","volume":"21","author":"Levitt","year":"1981","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0085|cit85","unstructured":"Levitt M Faiman C Hawks R Wilson A Randomized double blind comparison of delta-9-tetrahydrocannabinol and marijuana as chemotherapy antiemetics [abstract] Proceedings - Annual Meeting of American Society of Clinical Oncology 1984 3 91, Abstract C 354"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/PPO.0b013e31816a0f07","article-title":"Chemotherapy-induced nausea and vomiting","volume":"14","author":"Lohr","year":"2008","journal-title":"Cancer Journal"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0087|cit87","first-page":"C","article-title":"A randomized double-blind cross-over comparison of the antiemetic activity of levonantradol and prochlorperazine","volume":"1","author":"Long","year":"1982","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD009464.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2354.2008.00917.x","article-title":"Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis","volume":"17","author":"Machado Rocha","year":"2008","journal-title":"European Journal of Cancer Care"},{"issue":"4","key":"10.1002\/14651858.CD009464.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF00450585","article-title":"Toward drugs derived from cannabis","volume":"65","author":"Mechoulam","year":"1978","journal-title":"Naturwissenschaften"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009464.pub2-BIB0090|cit90","first-page":"16","article-title":"Recent advantages in cannabinoid research","volume":"6","author":"Mechoulam","year":"1999","journal-title":"Forschende Komplementarmedizin"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1155\/2001\/183057","article-title":"The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection","volume":"6","author":"Mechoulam","year":"2001","journal-title":"Pain Research and Management"},{"issue":"3","key":"10.1002\/14651858.CD009464.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1185\/030079907X167525","article-title":"Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting","volume":"23","author":"Meiri","year":"2007","journal-title":"Current Medical Research and Opinion"},{"issue":"3","key":"10.1002\/14651858.CD009464.pub2-BIB0093|cit93","first-page":"401","article-title":"Recent advances in the management of chemotherapy-induced emesis [Japanese]","volume":"13","author":"Murakami","year":"1986","journal-title":"Japanese Journal of Cancer Chemotherapy"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0094|cit94","doi-asserted-by":"crossref","unstructured":"Musty RE Rossi R Effects of smoked cannabis and oral DELTA9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: a review of state clinical trials Journal of Cannabis Therapeutics 2001 1 1 29","DOI":"10.1300\/J175v01n01_03"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0095|cit95","first-page":"30","article-title":"Nabilone (N) anti-emetic crossover study in cancer chemotherapy patients","volume":"19","author":"Nagy","year":"1978","journal-title":"American Association for Cancer Research and American Society of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD009464.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00003495-200969050-00002","article-title":"Pharmacological management of chemotherapy-induced nausea and vomiting","volume":"69","author":"Navari","year":"2009","journal-title":"Drugs"},{"issue":"4","key":"10.1002\/14651858.CD009464.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/14656560902731894","article-title":"Antiemetic control: toward a new standard of care for emetogenic chemotherapy","volume":"10","author":"Navari","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"8","key":"10.1002\/14651858.CD009464.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF01728184","article-title":"Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy","volume":"64","author":"Niederle","year":"1986","journal-title":"Klinische Wochenschrift"},{"issue":"4","key":"10.1002\/14651858.CD009464.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00000421-198708000-00014","article-title":"Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy","volume":"10","author":"Niiranen","year":"1987","journal-title":"American Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0100|cit100","first-page":"38","article-title":"A review of the antiemetic use of delta-9-tetrahydrocannabinol and prescribing requirements","volume":"39","author":"Nyman","year":"1982","journal-title":"Arizona Medicine"},{"issue":"11","key":"10.1002\/14651858.CD009464.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/archinte.1980.00330220019010","article-title":"Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis","volume":"140","author":"Orr","year":"1980","journal-title":"Archives of Internal Medicine"},{"issue":"8-9","key":"10.1002\/14651858.CD009464.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1002\/j.1552-4604.1981.tb02568.x","article-title":"Clinical trials with antiemetic agents in cancer patients receiving chemotherapy","volume":"21","author":"Penta","year":"1981","journal-title":"Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11096-010-9454-1","article-title":"Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics","volume":"33","author":"Perwitasari","year":"2011","journal-title":"International Journal of Clinical Pharmacy"},{"issue":"9","key":"10.1002\/14651858.CD009464.pub2-BIB0104|cit104","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007786.pub2","article-title":"Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood","author":"Phillips","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD009464.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0091-3057(91)90385-F","article-title":"Recent clinical experience with dronabinol","volume":"40","author":"Plasse","year":"1991","journal-title":"Pharmacology, Biochemistry and Behavior"},{"issue":"3","key":"10.1002\/14651858.CD009464.pub2-BIB0106|cit106","first-page":"129","article-title":"Cannabinoids, a myth or a scientific reality?","volume":"9","author":"Porta","year":"2002","journal-title":"Medicina Paliativa"},{"issue":"20","key":"10.1002\/14651858.CD009464.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1001\/jama.1981.03310450039020","article-title":"Delta 9-tetrahydrocannabinol in clinical oncology","volume":"245","author":"Poster","year":"1981","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD009464.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2002.20.12.2912","article-title":"Comparative efficacy of dronabinol and megestrol acetate","volume":"20","author":"Reynolds","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0109|cit109","unstructured":"Sallan S Zinberg N Frei E Oral delta 9 tetrahydrocannabinol (THC) in the prevention of vomiting (V) associated with cancer chemotherapy (CC) Annual Meeting, proceedings of the American Association for Cancer Research 1975 16 575"},{"issue":"3","key":"10.1002\/14651858.CD009464.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJM198001173020302","article-title":"Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine","volume":"302","author":"Sallan","year":"1980","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0111|cit111","first-page":"665","article-title":"Randomized crossover trial comparing the antiemetic efficacy of nabilone versus alizapride in patients (pts) with nonseminomatous testicular cancer (NSTC) receiving low-dose cisplatin therapy","volume":"26","author":"Schuette","year":"1985","journal-title":"Proceedings of the American Association for Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD009464.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/j.1552-4604.1984.tb01824.x","article-title":"Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine","volume":"24","author":"Sheidler","year":"1984","journal-title":"Journal of Clinical Pharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009464.pub2-BIB0113|cit113","first-page":"1","article-title":"Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis","volume":"5","author":"Slatkin","year":"2007","journal-title":"Journal of Supportive Oncology"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/157488507780619059","article-title":"Will medicinal cannabinoids prove to be useful clinically?","volume":"2","author":"Smith","year":"2007","journal-title":"Current Drug Therapy"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0115|cit115","first-page":"C","article-title":"A phase II randomized trial of the antiemetic activity of levonantradol (CP-50,556) in cancer patients receiving chemotherapy","volume":"1","author":"Stambaugh","year":"1982","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"11-12","key":"10.1002\/14651858.CD009464.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/j.1552-4604.1984.tb02756.x","article-title":"Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis","volume":"24","author":"Stambaugh Jr","year":"1984","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0117|cit117","unstructured":"Steele N Braun D O'Hehir M Young C Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis Cancer Treatment Reports 1979 64 2-3 219 24"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1139\/y90-045","article-title":"Cancer therapy, vomiting, and antiemetics","volume":"68","author":"Stewart","year":"1990","journal-title":"Canadian Journal of Physiology & Pharmacology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0119|cit119","unstructured":"Stuart JFB Welsh Sangster G Scullion M Cash H Kaye SB Calman KC The anti-emetic potential of oral levonantradol in patients receiving cancer chemotherapy British Journal of Cancer 1982 46 492"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0120|cit120","first-page":"143","article-title":"Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy","volume":"9","author":"Stuart-Harris","year":"1983","journal-title":"Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD009464.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.1980.03300380045025","article-title":"Marijuana for drug-induced nausea and vomiting","volume":"243","author":"Sweet","year":"1980","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD009464.pub2-BIB0122|cit122","first-page":"391","article-title":"Prophylaxis of chemotherapy-induced vomiting and nausea [Hungarian]","volume":"52","author":"Toth","year":"2008","journal-title":"Magyar Onkologia"},{"issue":"7303","key":"10.1002\/14651858.CD009464.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/bmj.323.7303.16","article-title":"Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review","volume":"323","author":"Tramer","year":"2001","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00000421-198504000-00006","article-title":"THC or compazine for the cancer chemotherapy patient - the UCLA study. Part II: patient drug preference","volume":"8","author":"Ungerleider","year":"1985","journal-title":"American Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0125|cit125","first-page":"253","article-title":"Intensive treatment scheduling of nabilone plus dexamethasone (DM) vs metoclopramide plus DM in cisplatin-induced emesis","volume":"5","author":"Venner","year":"1986","journal-title":"Proceedings of the American Society of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009464.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2165\/00003495-198300251-00006","article-title":"Review of cannabinoids and their antiemetic effectiveness","volume":"25","author":"Vincent","year":"1983","journal-title":"Drugs"},{"issue":"10","key":"10.1002\/14651858.CD009464.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-126-10-199705150-00008","article-title":"Medicinal applications of delta-9-tetrahydrocannabinol and marijuana","volume":"126","author":"Voth","year":"1997","journal-title":"Annals of Internal Medicine"},{"issue":"13","key":"10.1002\/14651858.CD009464.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1503\/cmaj.071178","article-title":"Adverse effects of medical cannabinoids: a systematic review","volume":"178","author":"Wang","year":"2008","journal-title":"Canadian Medical Association Journal"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00003495-198530020-00002","article-title":"Nabilone. A preliminary review of its pharmacological properties and therapeutic use","volume":"30","author":"Ward","year":"1985","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/TCRM.S1132","article-title":"A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting","volume":"4","author":"Ware","year":"2008","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"3","key":"10.1002\/14651858.CD009464.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1590\/S1516-44462008000300015","article-title":"Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action","volume":"30","author":"Zuardi","year":"2008","journal-title":"Revista Brasileira de Psiquiatria"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0132|cit132","first-page":"165","article-title":"Double-blind, randomised, crossover study of the antiemetic effect of levonantradol versus tetrahydrocannabinol","volume":"24","author":"Citron","year":"1983","journal-title":"Proceedings of the American Association of Cancer Research"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0133|cit133","first-page":"163","article-title":"Levonantradol vs prochlorperazine as parenteral antiemetics in cancer patients receiving cisplatin chemotherapy","volume":"24","author":"Earhart","year":"1983","journal-title":"Proceedings of the American Association for Cancer Research."},{"key":"10.1002\/14651858.CD009464.pub2-BIB0134|cit134","first-page":"S209","article-title":"Dronabinol for the prevention of nausea from cyclophosphamide and\/or adriamycin","volume":"20","author":"Harden-Harrison","year":"2012","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0135|cit135","doi-asserted-by":"crossref","unstructured":"Jhangiani H Vredenburgh J Barbato L Yang H Yang H M Baranowski V Dronabinol or ondansetron alone and combined for delayed chemotherapy-induced nausea and vomiting (CINV) Abstracts for the 47th Annual Meeting of the American Society of Hematology; 2005 Dec 10-13; Atlanta, Georgia 2005 106 477","DOI":"10.1182\/blood.V106.11.5555.5555"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0136|cit136","first-page":"67","article-title":"Pilot and definitive randomised double-blind placebocontrolled trials evaluating an oral cannabinoid-rich THC\/CBD cannabis extract for secondary prevention of chemotherapyinduced nausea and vomiting (CINV)","volume":"13","author":"Mersiades","year":"2017","journal-title":"Asia-pacific journal of clinical oncology"},{"issue":"8-9 Suppl","key":"10.1002\/14651858.CD009464.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.1002\/j.1552-4604.1981.tb02571.x","article-title":"Comparative trial of the antiemetic effects of THC and haloperidol","volume":"21","author":"Neidhart","year":"1981","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0305-7372(84)90010-0","article-title":"Advances in anti-emetic therapy","volume":"11","author":"Barowski","year":"1984","journal-title":"Cancer Treatment Reviews"},{"issue":"31","key":"10.1002\/14651858.CD009464.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"29","author":"Basch","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1634\/theoncologist.2013-0359","article-title":"Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects","volume":"19","author":"Beusterien","year":"2014","journal-title":"Oncologist"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0141|cit141","volume-title":"The Marijuana Conviction: a History of Marijuana Prohibition in the United States","author":"Bonnie","year":"1974"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0142|cit142","volume-title":"Statistical power analysis for the behavioural sciences","year":"1988"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0893-133X(00)00197-4","article-title":"Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB (1) receptor antagonist\/inverse agonist SR 141716A","volume":"24","author":"Darmani","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD009464.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/bjc.1997.507","article-title":"Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists","volume":"76","author":"Boer-Dennert","year":"1997","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/9780470693926.ch15","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context","author":"Deeks","year":"2001"},{"issue":"Suppl XIX","key":"10.1002\/14651858.CD009464.pub2-BIB0146|cit146","first-page":"S68","article-title":"Measurement of success: parameters of efficacy","volume":"66","author":"De Mulder","year":"1992","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0148|cit148","first-page":"149","article-title":"Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer","volume":"3","author":"Dubey","year":"2005","journal-title":"Journal of Supportive Oncology"},{"issue":"9","key":"10.1002\/14651858.CD009464.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.1999.17.9.2971","article-title":"Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines","volume":"17","author":"Gralla","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0150|cit150","unstructured":"Gralla RJ Roila F Tonato M Herstedt J MASCC antiemetic guidelines, 2013 www.mascc.org\/antiemetic-guidelines"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0151|cit151","first-page":"55","volume-title":"Pharmacology, Toxicology and Therapeutic Potential","author":"Grotenhermen","year":"2002"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0153|cit153","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"3-4","key":"10.1002\/14651858.CD009464.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1081\/CRP-200049997","article-title":"Efficacy of current antiemetic treatments for preventing delayed chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials","volume":"21","author":"Huang","year":"2004","journal-title":"Clinical Research and Regulatory Affairs"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2000.18.19.3409","article-title":"Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence","volume":"18","author":"Ioannidis","year":"2000","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD009464.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1517\/14656566.2013.776541","article-title":"Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients","volume":"14","author":"Janelsins","year":"2013","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0157|cit157","first-page":"131","volume-title":"Depend\u00eancia de Drogas","author":"Karniol","year":"2001"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10549-013-2727-3","article-title":"Preference weights for chemotherapy side effects from the perspective of women with breast cancer","volume":"142","author":"Kuchuk","year":"2013","journal-title":"Breast Cancer Research and Treatment"},{"issue":"5","key":"10.1002\/14651858.CD009464.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2354.2008.00917.x","article-title":"Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis","volume":"17","author":"Machado Rocha","year":"2008","journal-title":"European Journal of Cancer Care"},{"issue":"Suppl XIX","key":"10.1002\/14651858.CD009464.pub2-BIB0160|cit160","first-page":"S46","article-title":"Myths and realities of antiemetic treatment","volume":"66","author":"Martin","year":"1992","journal-title":"British Journal of Cancer"},{"issue":"8","key":"10.1002\/14651858.CD009464.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1023\/A:1008471812316","article-title":"Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)","volume":"9","author":"Multinational Association of Supportive Care in Cancer (MASCC)","year":"1998","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0006-2952(95)00109-D","article-title":"Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors","volume":"50","author":"Mechoulam","year":"1995","journal-title":"Biochemical Pharmacology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0163|cit163","doi-asserted-by":"crossref","unstructured":"National Comprehensive Cancer Network (NCCN) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) Antiemesis Version 2, 2014 www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp, last retrieved 09.11.15","DOI":"10.6004\/jnccn.2013.0123"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0164|cit164","unstructured":"National Comprehensive Cancer Network (NCCN) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Antiemesis Version 2 http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf, last retrieved 09.11.15"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000227055","article-title":"Methodology in anti-emetic trials","volume":"49","author":"Olver","year":"1992","journal-title":"Oncology"},{"issue":"Suppl XIX","key":"10.1002\/14651858.CD009464.pub2-BIB0166|cit166","first-page":"S30","article-title":"Antiemetic study design: desirable objectives, stratifications and analyses","volume":"66","author":"Olver","year":"1992","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0167|cit167","first-page":"140","article-title":"Two decades of progress in treating chemotherapy induced emesis","volume":"28","author":"Olver","year":"2004","journal-title":"Cancer Forum"},{"issue":"5","key":"10.1002\/14651858.CD009464.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.1984.2.5.484","article-title":"Methodologic issues in trials of antiemetics","volume":"2","author":"Pater","year":"1984","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00002820-198402000-00003","article-title":"Development of reliable and valid measures of nausea and vomiting","volume":"7","author":"Rhodes","year":"1984","journal-title":"Cancer Nursing"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/alcalc\/agh110","article-title":"The endocannabinoid system: physiology and pharmacology","volume":"40(1)","author":"Rodr\u00edguez de Fonseca","year":"2005","journal-title":"Alcohol and Alcoholism"},{"issue":"5","key":"10.1002\/14651858.CD009464.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference","volume":"21","author":"Roila","year":"2010","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD009464.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1517\/14740338.2013.830710","article-title":"Factors affecting patient's perception of anticancer treatments side-effects: an observational study","volume":"13","author":"Russo","year":"2014","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0173|cit173","first-page":"5","article-title":"Chemotherapy-induced nausea and vomiting: clinician and patient perspective","volume":"5","author":"Schwartzberg","year":"2007","journal-title":"Journal of Support Oncology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/bbrc.1995.2437","article-title":"2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain","volume":"215","author":"Sugiura","year":"1995","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"1","key":"10.1002\/14651858.CD009464.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1006\/gyno.2002.6807","article-title":"Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?","volume":"87","author":"Sun","year":"2002","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00520-002-0387-7","article-title":"Established and potential therapeutic applications of cannabinoids in oncology","volume":"11","author":"Walsh","year":"2003","journal-title":"Supportive Care in Cancer"},{"key":"10.1002\/14651858.CD009464.pub2-BIB0177|cit177","first-page":"1601","article-title":"Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma","volume":"66","author":"Wilcox","year":"1982","journal-title":"Cancer Treatment Reports"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD009464.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T03:41:42Z","timestamp":1671594102000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009464.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,11,12]]},"references-count":177,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009464.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,12]]}}}